The Need

The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addressing this urgent need for an enhanced vaccine platform is crucial to overcoming the ongoing global pandemic.

The Technology

HexaPro VSV represents a cutting-edge advancement in COVID-19 vaccine technology. Leveraging the highly efficient Vesicular Stomatitis Virus (VSV) vector, HexaPro introduces a stabilized form of the spike (S) glycoprotein, HexaPro, which exhibits superior expression, stability, and resistance to environmental stressors compared to the prevalent preS-2P variant. This breakthrough technology enhances the immunogenicity of the vaccine and ensures a robust defense against evolving SARS-CoV-2 variants.

Commercial Applications

• Next-Generation COVID-19 Vaccines: HexaPro VSV serves as a foundation for the development of next-generation COVID-19 vaccines with improved durability and efficacy.

• Pan-Coronavirus Vaccines: HexaPro VSV extends its applicability beyond SARS-CoV-2, offering a promising solution for developing FDA-approved vaccines targeting a spectrum of Coronaviruses, including economically impactful variants in animals.

• Outbreak Control: The rapid and efficient replication of VSV makes it an ideal candidate for controlling outbreaks of highly pathogenic agents, providing a versatile tool for immediate response.

• Cross-Species Vaccine Development: HexaPro VSV has the potential to revolutionize vaccine development across species, addressing critical needs in both human and animal health.

Benefits/Advantages

• Enhanced Immunogenicity: HexaPro VSV exhibits higher expression levels, increased stability, and greater resistance to environmental stressors, contributing to enhanced immunogenicity and prolonged protection.

• Versatility: As a vaccine vector, VSV demonstrates versatility by accommodating foreign genes, making it a powerful tool in the development of vaccines for various pathogens, including filoviruses, arenaviruses, and other coronaviruses.

• Rapid Response: The rapid and efficient replication of VSV enables swift responses to outbreaks, ensuring timely intervention and control of highly pathogenic agents.

• Safety Assurance: Unlike DNA viruses, VSV RNAs do not recombine or integrate into host cell DNA, ensuring a high level of safety as a vaccine vector.

HexaPro VSV represents a significant leap forward in the fight against COVID-19 and beyond, offering a versatile and durable solution to meet the evolving challenges posed by emerging viral variants.